Aurobindo Pharma Ltd(IN:AUROPHARMA)
₹1,825.00-18.00 (-0.98%)
IN:AUROPHARMA
Aurobindo Pharma Ltd financials statements
₹1,825.00
At close:-18.00 (-0.98%)
Want to see IN:AUROPHARMA full AI Analyst Report?
Aurobindo Pharma Ltd (AUROPHARMA) Financial Statements
7 Followers
Aurobindo Pharma Ltd Financial Overview
Aurobindo Pharma Ltd's market cap is currently ₹1.06T. The company's EPS TTM is ₹64.00; its P/E ratio is 26.50; and it has a dividend yield of 0.38%. Aurobindo Pharma Ltd is estimated to report earnings on February 14, 2027, and the estimated EPS forecast is ₹21.48. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Mar 25 | Mar 24 | Mar 23 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | ₹ 336.53B | ₹ 317.24B | ₹ 290.02B | ₹ 248.55B | ₹ 234.55B |
| Gross Profit | ₹ 131.96B | ₹ 182.40B | ₹ 160.16B | ₹ 132.14B | ₹ 130.06B |
| Operating Income | ₹ 50.78B | ₹ 120.01B | ₹ 104.50B | ₹ 81.05B | ₹ 78.06B |
| EBITDA | ₹ 72.74B | ₹ 65.78B | ₹ 58.83B | ₹ 37.56B | ₹ 44.33B |
| Net Income | ₹ 35.05B | ₹ 34.86B | ₹ 31.73B | ₹ 19.27B | ₹ 26.48B |
| Balance Sheet | |||||
| Cash & Short-Term Investments | ₹ 106.18B | ₹ 82.36B | ₹ 63.25B | ₹ 62.24B | ₹ 45.58B |
| Total Assets | ₹ 585.02B | ₹ 497.85B | ₹ 450.72B | ₹ 398.90B | ₹ 339.22B |
| Total Debt | ₹ 80.73B | ₹ 82.63B | ₹ 66.48B | ₹ 52.86B | ₹ 32.79B |
| Net Debt | ₹ -17.97B | ₹ 273.80M | ₹ 32.54B | ₹ 8.90B | ₹ -8.84B |
| Total Liabilities | ₹ 206.19B | ₹ 171.38B | ₹ 152.21B | ₹ 130.38B | ₹ 93.48B |
| Stockholders' Equity | ₹ 378.91B | ₹ 326.53B | ₹ 298.43B | ₹ 268.40B | ₹ 245.76B |
| Cash Flow | |||||
| Free Cash Flow | ₹ 28.27B | ₹ 19.57B | ₹ -11.27B | ₹ -3.34B | ₹ 23.12B |
| Operating Cash Flow | ₹ 55.13B | ₹ 39.25B | ₹ 24.35B | ₹ 23.87B | ₹ 50.16B |
| Investing Cash Flow | ₹ -37.89B | ₹ -18.76B | ₹ -42.56B | ₹ -39.78B | ₹ -32.12B |
| Financing Cash Flow | ₹ -9.25B | ₹ 1.20B | ₹ 8.00B | ₹ 18.14B | ₹ -29.69B |
Currency in INR
